Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Determining the incidence of familiality in ALS: A study of temporal trends in Ireland from 1994 to 2016.

Ryan M, Heverin M, Doherty MA, Davis N, Corr EM, Vajda A, Pender N, McLaughlin R, Hardiman O.

Neurol Genet. 2018 May 18;4(3):e239. doi: 10.1212/NXG.0000000000000239. eCollection 2018 Jun.

2.

Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model.

Westeneng HJ, Debray TPA, Visser AE, van Eijk RPA, Rooney JPK, Calvo A, Martin S, McDermott CJ, Thompson AG, Pinto S, Kobeleva X, Rosenbohm A, Stubendorff B, Sommer H, Middelkoop BM, Dekker AM, van Vugt JJFA, van Rheenen W, Vajda A, Heverin M, Kazoka M, Hollinger H, Gromicho M, Körner S, Ringer TM, Rödiger A, Gunkel A, Shaw CE, Bredenoord AL, van Es MA, Corcia P, Couratier P, Weber M, Grosskreutz J, Ludolph AC, Petri S, de Carvalho M, Van Damme P, Talbot K, Turner MR, Shaw PJ, Al-Chalabi A, Chiò A, Hardiman O, Moons KGM, Veldink JH, van den Berg LH.

Lancet Neurol. 2018 May;17(5):423-433. doi: 10.1016/S1474-4422(18)30089-9. Epub 2018 Mar 26.

3.

Longitudinal predictors of caregiver burden in amyotrophic lateral sclerosis: a population-based cohort of patient-caregiver dyads.

Burke T, Hardiman O, Pinto-Grau M, Lonergan K, Heverin M, Tobin K, Staines A, Galvin M, Pender N.

J Neurol. 2018 Apr;265(4):793-808. doi: 10.1007/s00415-018-8770-6. Epub 2018 Feb 2.

PMID:
29396678
4.

Measuring reliable change in cognition using the Edinburgh Cognitive and Behavioural ALS Screen (ECAS).

Crockford C, Newton J, Lonergan K, Madden C, Mays I, O'Sullivan M, Costello E, Pinto-Grau M, Vajda A, Heverin M, Pender N, Al-Chalabi A, Hardiman O, Abrahams S.

Amyotroph Lateral Scler Frontotemporal Degener. 2018 Feb;19(1-2):65-73. doi: 10.1080/21678421.2017.1407794. Epub 2017 Dec 7.

PMID:
29214872
5.

Characteristic Increases in EEG Connectivity Correlate With Changes of Structural MRI in Amyotrophic Lateral Sclerosis.

Nasseroleslami B, Dukic S, Broderick M, Mohr K, Schuster C, Gavin B, McLaughlin R, Heverin M, Vajda A, Iyer PM, Pender N, Bede P, Lalor EC, Hardiman O.

Cereb Cortex. 2017 Nov 9:1-15. doi: 10.1093/cercor/bhx301. [Epub ahead of print]

PMID:
29136131
6.

Clustering of Neuropsychiatric Disease in First-Degree and Second-Degree Relatives of Patients With Amyotrophic Lateral Sclerosis.

O'Brien M, Burke T, Heverin M, Vajda A, McLaughlin R, Gibbons J, Byrne S, Pinto-Grau M, Elamin M, Pender N, Hardiman O.

JAMA Neurol. 2017 Dec 1;74(12):1425-1430. doi: 10.1001/jamaneurol.2017.2699.

PMID:
29049464
7.

Mismatch Negativity as an Indicator of Cognitive Sub-Domain Dysfunction in Amyotrophic Lateral Sclerosis.

Iyer PM, Mohr K, Broderick M, Gavin B, Burke T, Bede P, Pinto-Grau M, Pender NP, McLaughlin R, Vajda A, Heverin M, Lalor EC, Hardiman O, Nasseroleslami B.

Front Neurol. 2017 Aug 15;8:395. doi: 10.3389/fneur.2017.00395. eCollection 2017.

8.

The path to specialist multidisciplinary care in amyotrophic lateral sclerosis: A population- based study of consultations, interventions and costs.

Galvin M, Ryan P, Maguire S, Heverin M, Madden C, Vajda A, Normand C, Hardiman O.

PLoS One. 2017 Jun 22;12(6):e0179796. doi: 10.1371/journal.pone.0179796. eCollection 2017.

9.

Assessing behavioural changes in ALS: cross-validation of ALS-specific measures.

Pinto-Grau M, Costello E, O'Connor S, Elamin M, Burke T, Heverin M, Pender N, Hardiman O.

J Neurol. 2017 Jul;264(7):1397-1401. doi: 10.1007/s00415-017-8536-6. Epub 2017 Jun 9.

PMID:
28600595
10.

A Cross-sectional population-based investigation into behavioral change in amyotrophic lateral sclerosis: subphenotypes, staging, cognitive predictors, and survival.

Burke T, Pinto-Grau M, Lonergan K, Bede P, O'Sullivan M, Heverin M, Vajda A, McLaughlin RL, Pender N, Hardiman O.

Ann Clin Transl Neurol. 2017 Apr 11;4(5):305-317. doi: 10.1002/acn3.407. eCollection 2017 May.

11.

Genetic testing in ALS: A survey of current practices.

Vajda A, McLaughlin RL, Heverin M, Thorpe O, Abrahams S, Al-Chalabi A, Hardiman O.

Neurology. 2017 Mar 7;88(10):991-999. doi: 10.1212/WNL.0000000000003686. Epub 2017 Feb 3. Review.

12.

Screening for cognitive dysfunction in ALS: validation of the Edinburgh Cognitive and Behavioural ALS Screen (ECAS) using age and education adjusted normative data.

Pinto-Grau M, Burke T, Lonergan K, McHugh C, Mays I, Madden C, Vajda A, Heverin M, Elamin M, Hardiman O, Pender N.

Amyotroph Lateral Scler Frontotemporal Degener. 2017 Feb;18(1-2):99-106. doi: 10.1080/21678421.2016.1249887. Epub 2016 Nov 28.

PMID:
27894201
13.

Identifying behavioural changes in ALS: Validation of the Beaumont Behavioural Inventory (BBI).

Elamin M, Pinto-Grau M, Burke T, Bede P, Rooney J, O'Sullivan M, Lonergan K, Kirby E, Quinlan E, Breen N, Vajda A, Heverin M, Pender N, Hardiman O.

Amyotroph Lateral Scler Frontotemporal Degener. 2017 Feb;18(1-2):68-73. doi: 10.1080/21678421.2016.1248976. Epub 2016 Nov 28.

PMID:
27894191
14.

What does the ALSFRS-R really measure? A longitudinal and survival analysis of functional dimension subscores in amyotrophic lateral sclerosis.

Rooney J, Burke T, Vajda A, Heverin M, Hardiman O.

J Neurol Neurosurg Psychiatry. 2017 May;88(5):381-385. doi: 10.1136/jnnp-2016-314661. Epub 2016 Nov 25.

PMID:
27888187
15.

C9orf72 expansion differentially affects males with spinal onset amyotrophic lateral sclerosis.

Rooney J, Fogh I, Westeneng HJ, Vajda A, McLaughlin R, Heverin M, Jones A, van Eijk R, Calvo A, Mazzini L, Shaw C, Morrison K, Shaw PJ, Robberecht W, Van Damme P, Al-Chalabi A, van den Berg L, Chiò A, Veldink J, Hardiman O.

J Neurol Neurosurg Psychiatry. 2017 Apr;88(4):281. doi: 10.1136/jnnp-2016-314093. Epub 2016 Sep 23.

PMID:
27663272
16.

Age-period-cohort analysis of trends in amyotrophic lateral sclerosis incidence.

Tobin K, Gilthorpe MS, Rooney J, Heverin M, Vajda A, Staines A, Hardiman O.

J Neurol. 2016 Oct;263(10):1919-26. doi: 10.1007/s00415-016-8215-z. Epub 2016 Jul 2.

PMID:
27372451
17.

Survival analysis of geospatial factors in the Irish ALS cohort.

Rooney J, Heverin M, Vajda A, Burke T, Galvin M, Tobin K, Elamin M, Staines A, Hardiman O.

Amyotroph Lateral Scler Frontotemporal Degener. 2016 Oct - Nov;17(7-8):555-560. Epub 2016 May 4.

PMID:
27145090
18.

No association between soil constituents and amyotrophic lateral sclerosis relative risk in Ireland.

Rooney J, Vajda A, Heverin M, Crampsie A, Tobin K, McLaughlin R, Staines A, Hardiman O.

Environ Res. 2016 May;147:102-7. doi: 10.1016/j.envres.2016.01.038. Epub 2016 Feb 6.

PMID:
26855128
19.

On the regulatory importance of 27-hydroxycholesterol in mouse liver.

Heverin M, Ali Z, Olin M, Tillander V, Joibari MM, Makoveichuk E, Leitersdorf E, Warner M, Olivercrona G, Gustafsson JÅ, Björkhem I.

J Steroid Biochem Mol Biol. 2017 May;169:10-21. doi: 10.1016/j.jsbmb.2016.02.001. Epub 2016 Feb 3.

PMID:
26851362
20.

Patient journey to a specialist amyotrophic lateral sclerosis multidisciplinary clinic: an exploratory study.

Galvin M, Madden C, Maguire S, Heverin M, Vajda A, Staines A, Hardiman O.

BMC Health Serv Res. 2015 Dec 23;15:571. doi: 10.1186/s12913-015-1229-x.

21.

Social deprivation and population density are not associated with small area risk of amyotrophic lateral sclerosis.

Rooney JP, Tobin K, Crampsie A, Vajda A, Heverin M, McLaughlin R, Staines A, Hardiman O.

Environ Res. 2015 Oct;142:141-7. doi: 10.1016/j.envres.2015.06.024. Epub 2015 Jul 2.

PMID:
26142719
22.

Spatial cluster analysis of population amyotrophic lateral sclerosis risk in Ireland.

Rooney J, Vajda A, Heverin M, Elamin M, Crampsie A, McLaughlin R, Staines A, Hardiman O.

Neurology. 2015 Apr 14;84(15):1537-44. doi: 10.1212/WNL.0000000000001477. Epub 2015 Mar 13.

PMID:
25770197
23.

Homozygosity mapping in an Irish ALS case-control cohort describes local demographic phenomena and points towards potential recessive risk loci.

McLaughlin RL, Kenna KP, Vajda A, Heverin M, Byrne S, Donaghy CG, Cronin S, Bradley DG, Hardiman O.

Genomics. 2015 Apr;105(4):237-41. doi: 10.1016/j.ygeno.2015.01.002. Epub 2015 Jan 23.

24.

A multidisciplinary clinic approach improves survival in ALS: a comparative study of ALS in Ireland and Northern Ireland.

Rooney J, Byrne S, Heverin M, Tobin K, Dick A, Donaghy C, Hardiman O.

J Neurol Neurosurg Psychiatry. 2015 May;86(5):496-501. doi: 10.1136/jnnp-2014-309601. Epub 2014 Dec 30.

PMID:
25550416
25.

27-hydroxycholesterol mediates negative effects of dietary cholesterol on cognition in mice.

Heverin M, Maioli S, Pham T, Mateos L, Camporesi E, Ali Z, Winblad B, Cedazo-Minguez A, Björkhem I.

Behav Brain Res. 2015 Feb 1;278:356-9. doi: 10.1016/j.bbr.2014.10.018. Epub 2014 Oct 18.

PMID:
25453744
26.

Analysis of amyotrophic lateral sclerosis as a multistep process: a population-based modelling study.

Al-Chalabi A, Calvo A, Chio A, Colville S, Ellis CM, Hardiman O, Heverin M, Howard RS, Huisman MHB, Keren N, Leigh PN, Mazzini L, Mora G, Orrell RW, Rooney J, Scott KM, Scotton WJ, Seelen M, Shaw CE, Sidle KS, Swingler R, Tsuda M, Veldink JH, Visser AE, van den Berg LH, Pearce N.

Lancet Neurol. 2014 Nov;13(11):1108-1113. doi: 10.1016/S1474-4422(14)70219-4. Epub 2014 Oct 7.

27.

An exploratory spatial analysis of ALS incidence in Ireland over 17.5 years (1995-July 2013).

Rooney J, Heverin M, Vajda A, Crampsie A, Tobin K, Byrne S, Staines A, Hardiman O.

PLoS One. 2014 May 27;9(5):e96556. doi: 10.1371/journal.pone.0096556. eCollection 2014.

28.

Fecundity in ALS.

Byrne S, Heverin M, Bede P, Elamin M, Hardiman O.

Amyotroph Lateral Scler Frontotemporal Degener. 2014 Jun;15(3-4):204-6. doi: 10.3109/21678421.2013.865237. Epub 2014 Jan 31. No abstract available.

PMID:
24479554
29.

Survival analysis of irish amyotrophic lateral sclerosis patients diagnosed from 1995-2010.

Rooney J, Byrne S, Heverin M, Corr B, Elamin M, Staines A, Goldacre B, Hardiman O.

PLoS One. 2013 Sep 30;8(9):e74733. doi: 10.1371/journal.pone.0074733. eCollection 2013.

30.

Intermediate repeat expansion length in C9orf72 may be pathological in amyotrophic lateral sclerosis.

Byrne S, Heverin M, Elamin M, Walsh C, Hardiman O.

Amyotroph Lateral Scler Frontotemporal Degener. 2014 Mar;15(1-2):148-50. doi: 10.3109/21678421.2013.838586. Epub 2013 Sep 23.

PMID:
24053774
31.

Delineating the genetic heterogeneity of ALS using targeted high-throughput sequencing.

Kenna KP, McLaughlin RL, Byrne S, Elamin M, Heverin M, Kenny EM, Cormican P, Morris DW, Donaghy CG, Bradley DG, Hardiman O.

J Med Genet. 2013 Nov;50(11):776-83. doi: 10.1136/jmedgenet-2013-101795. Epub 2013 Jul 23.

32.

Is it possible to improve memory function by upregulation of the cholesterol 24S-hydroxylase (CYP46A1) in the brain?

Maioli S, Båvner A, Ali Z, Heverin M, Ismail MA, Puerta E, Olin M, Saeed A, Shafaati M, Parini P, Cedazo-Minguez A, Björkhem I.

PLoS One. 2013 Jul 16;8(7):e68534. doi: 10.1371/journal.pone.0068534. Print 2013.

33.

Sulphatation does not appear to be a protective mechanism to prevent oxysterol accumulation in humans and mice.

Acimovic J, Lövgren-Sandblom A, Olin M, Ali Z, Heverin M, Schüle R, Schöls L, Fischler B, Fickert P, Trauner M, Björkhem I.

PLoS One. 2013 Jul 3;8(7):e68031. doi: 10.1371/journal.pone.0068031. Print 2013.

34.

Aggregation of neurologic and neuropsychiatric disease in amyotrophic lateral sclerosis kindreds: a population-based case-control cohort study of familial and sporadic amyotrophic lateral sclerosis.

Byrne S, Heverin M, Elamin M, Bede P, Lynch C, Kenna K, MacLaughlin R, Walsh C, Al Chalabi A, Hardiman O.

Ann Neurol. 2013 Nov;74(5):699-708. doi: 10.1002/ana.23969. Epub 2013 Sep 10.

PMID:
23836460
35.

On the regulatory role of side-chain hydroxylated oxysterols in the brain. Lessons from CYP27A1 transgenic and Cyp27a1(-/-) mice.

Ali Z, Heverin M, Olin M, Acimovic J, Lövgren-Sandblom A, Shafaati M, Båvner A, Meiner V, Leitersdorf E, Björkhem I.

J Lipid Res. 2013 Apr;54(4):1033-43. doi: 10.1194/jlr.M034124. Epub 2013 Jan 2.

36.

Bi-lateral changes to hippocampal cholesterol levels during epileptogenesis and in chronic epilepsy following focal-onset status epilepticus in mice.

Heverin M, Engel T, Meaney S, Jimenez-Mateos EM, Al-Saudi R, Henshall DC.

Brain Res. 2012 Oct 22;1480:81-90. doi: 10.1016/j.brainres.2012.08.018. Epub 2012 Aug 17.

PMID:
22921849
37.

Proteomic analysis of 14-3-3 zeta binding proteins in the mouse hippocampus.

Heverin M, Brennan GP, Koehler CJ, Treumann A, Henshall DC.

Int J Physiol Pathophysiol Pharmacol. 2012;4(2):74-83. Epub 2012 Jun 23.

38.

Differential diagnosis in patients with suspected bile acid synthesis defects.

Haas D, Gan-Schreier H, Langhans CD, Rohrer T, Engelmann G, Heverin M, Russell DW, Clayton PT, Hoffmann GF, Okun JG.

World J Gastroenterol. 2012 Mar 14;18(10):1067-76. doi: 10.3748/wjg.v18.i10.1067.

39.

Cognitive and clinical characteristics of patients with amyotrophic lateral sclerosis carrying a C9orf72 repeat expansion: a population-based cohort study.

Byrne S, Elamin M, Bede P, Shatunov A, Walsh C, Corr B, Heverin M, Jordan N, Kenna K, Lynch C, McLaughlin RL, Iyer PM, O'Brien C, Phukan J, Wynne B, Bokde AL, Bradley DG, Pender N, Al-Chalabi A, Hardiman O.

Lancet Neurol. 2012 Mar;11(3):232-40. doi: 10.1016/S1474-4422(12)70014-5. Epub 2012 Feb 3. Erratum in: Lancet Neurol. 2012 May;11(5):388.

40.

Side chain-oxidized oxysterols regulate the brain renin-angiotensin system through a liver X receptor-dependent mechanism.

Mateos L, Ismail MA, Gil-Bea FJ, Schüle R, Schöls L, Heverin M, Folkesson R, Björkhem I, Cedazo-Mínguez A.

J Biol Chem. 2011 Jul 22;286(29):25574-85. doi: 10.1074/jbc.M111.236877. Epub 2011 May 31.

41.

The desmosterolosis phenotype: spasticity, microcephaly and micrognathia with agenesis of corpus callosum and loss of white matter.

Zolotushko J, Flusser H, Markus B, Shelef I, Langer Y, Heverin M, Björkhem I, Sivan S, Birk OS.

Eur J Hum Genet. 2011 Sep;19(9):942-6. doi: 10.1038/ejhg.2011.74. Epub 2011 May 11.

42.

Studies on the cholesterol-free mouse: strong activation of LXR-regulated hepatic genes when replacing cholesterol with desmosterol.

Heverin M, Meaney S, Brafman A, Shafir M, Olin M, Shafaati M, von Bahr S, Larsson L, Lövgren-Sandblom A, Diczfalusy U, Parini P, Feinstein E, Björkhem I.

Arterioscler Thromb Vasc Biol. 2007 Oct;27(10):2191-7. Epub 2007 Aug 30.

43.

Novel LC-MS/MS method for assay of 7alpha-hydroxy-4-cholesten-3-one in human plasma. Evidence for a significant extrahepatic metabolism.

Lövgren-Sandblom A, Heverin M, Larsson H, Lundström E, Wahren J, Diczfalusy U, Björkhem I.

J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Sep 1;856(1-2):15-9. Epub 2007 May 29.

PMID:
17561450
44.

Novel route for elimination of brain oxysterols across the blood-brain barrier: conversion into 7alpha-hydroxy-3-oxo-4-cholestenoic acid.

Meaney S, Heverin M, Panzenboeck U, Ekström L, Axelsson M, Andersson U, Diczfalusy U, Pikuleva I, Wahren J, Sattler W, Björkhem I.

J Lipid Res. 2007 Apr;48(4):944-51. Epub 2007 Jan 24.

45.
46.

Oxysterols and Alzheimer's disease.

Björkhem I, Heverin M, Leoni V, Meaney S, Diczfalusy U.

Acta Neurol Scand Suppl. 2006;185:43-9. Review.

PMID:
16866910
47.

Studies on the transcriptional regulation of cholesterol 24-hydroxylase (CYP46A1): marked insensitivity toward different regulatory axes.

Ohyama Y, Meaney S, Heverin M, Ekström L, Brafman A, Shafir M, Andersson U, Olin M, Eggertsen G, Diczfalusy U, Feinstein E, Björkhem I.

J Biol Chem. 2006 Feb 17;281(7):3810-20. Epub 2005 Nov 30.

48.

Brain cholesterol synthesis in mice is affected by high dose of simvastatin but not of pravastatin.

Thelen KM, Rentsch KM, Gutteck U, Heverin M, Olin M, Andersson U, von Eckardstein A, Björkhem I, Lütjohann D.

J Pharmacol Exp Ther. 2006 Mar;316(3):1146-52. Epub 2005 Nov 10.

49.

Crossing the barrier: net flux of 27-hydroxycholesterol into the human brain.

Heverin M, Meaney S, Lütjohann D, Diczfalusy U, Wahren J, Björkhem I.

J Lipid Res. 2005 May;46(5):1047-52. Epub 2005 Mar 1.

50.

Generation of viable cholesterol-free mice.

Wechsler A, Brafman A, Shafir M, Heverin M, Gottlieb H, Damari G, Gozlan-Kelner S, Spivak I, Moshkin O, Fridman E, Becker Y, Skaliter R, Einat P, Faerman A, Björkhem I, Feinstein E.

Science. 2003 Dec 19;302(5653):2087. No abstract available.

Supplemental Content

Loading ...
Support Center